Page 24 - Zai Lab News Today

Penn downgraded, Roblox upgraded: Wall Street's top analyst calls

– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 –– Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 –– INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-...

NEW YORK, Aug. 06, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating...

Real-time index price for Nasdaq US Distillers & Vintners Index (NQDV), along with buy or sell indicators, analysis, charts, historical performance, news and more

Building a Global Biopharma Leader August 2023 Forward-Looking Statements This presentation...

Zai Lab (NASDAQ:ZLAB – Get Free Report) will announce its earnings results after the market closes on Monday, August 7th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link. Zai Lab (NASDAQ:ZLAB – Get […]

Schrödinger Inc (NASDAQ: SDGR) shares are down after the company, on Wednesday, 

Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Immune Therapeutics (OTCMKTS:IMUN – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Profitability This table compares Regeneron Pharmaceuticals and Immune […]